← Back to Search

Physician Education about Gabapentinoid Prescription for Overmedication (GABA-WHY Trial)

N/A
Waitlist Available
Led By Emily G McDonald, MD, MSc
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8-weeks post-hospital discharge
Awards & highlights

GABA-WHY Trial Summary

This trial will distribute educational brochures about deprescribing gabapentinoids to inpatients in two hospitals in Canada. This study aims to evaluate the effectiveness of this intervention on increasing gabapentinoid deprescription rates among study participants compared to control following hospital discharge.

Eligible Conditions
  • Overmedication
  • Gabapentin
  • Pregabalin

GABA-WHY Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8-weeks post-hospital discharge
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8-weeks post-hospital discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gabapentinoid Discontinuation or Dose Reduction With Intention to Stop
Secondary outcome measures
Chronic Pain Intensity
Cognition
Gabapentinoid Dose Reduction Without Intention to Stop
+3 more

GABA-WHY Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: In-Hopsital Patient Educational Brochure and Physician Education about Gabapentinoid PrescriptionExperimental Treatment2 Interventions
During the intervention period, patients admitted to the study sites who qualify for the trial will receive an in-hospital educational brochure. Additionally, the medical team will attend an educational session about gabapentinoid prescription.
Group II: Usual Medical CareActive Control1 Intervention
During the control period, patients admitted to the study sites who qualify for the trial will receive a pharmacy medication reconciliation as part of usual medical care. Study participants will be informed that the goal of the trial is to evaluate medication use and medication changes after discharge, but they will not be informed that gabapentinoids are specifically being targeted. Medical staff will not receive specific information about the trial, or particular instructions with regards to deprescription during the control period.

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
442 Previous Clinical Trials
159,014 Total Patients Enrolled
Emily G McDonald, MD, MScPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies for participants in this medical experiment?

"According to the clinicaltrials.gov listing, this trial is currently open for enrollment and was posted on May 28th 2021 with a recent update taking place April 4th 2022."

Answered by AI

How many individuals are currently involved in the research project?

"Affirmative, the information on clinicaltrials.gov affirms that this trial, first published on May 28th 2021 is seeking participants. Recruitment of 160 patients between two different sites is required to move forward with the study."

Answered by AI
Recent research and studies
Expert Opinion on Drug SafetyJournal
Drug Safety Evaluation of Pregabalin
Toth, Cory. 2012. “Drug Safety Evaluation of Pregabalin”. Expert Opinion on Drug Safety. Informa Healthcare. doi:10.1517/14740338.2012.677026.
Pain MedicineJournal
Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other Cns-active Medications: A Cross-sectional Time Series Analysis
Kwok, Herman, Wayne Khuu, Kimberly Fernandes, Diana Martins, Mina Tadrous, Samantha Singh, David N. Juurlink, and Tara Gomes. 2017. “Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other Cns-active Medications: A Cross-sectional Time Series Analysis”. Pain Medicine. Oxford University Press (OUP). doi:10.1093/pm/pnw351.
PLOS MedicineJournal
Benefits and Safety of Gabapentinoids in Chronic Low Back Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Shanthanna, Harsha, Ian Gilron, Manikandan Rajarathinam, Rizq AlAmri, Sriganesh Kamath, Lehana Thabane, Philip J. Devereaux, and Mohit Bhandari. 2017. “Benefits and Safety of Gabapentinoids in Chronic Low Back Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials”. Edited by Alexander C. Tsai. PLOS Medicine. Public Library of Science (PLoS). doi:10.1371/journal.pmed.1002369.
Journal of Managed Care PharmacyJournal
Gabapentin Use in a Managed Medicaid Population
Hamer, Ann M., Dean G. Haxby, Bentson H. McFarland, and Kathy Ketchum. 2002. “Gabapentin Use in a Managed Medicaid Population”. Journal of Managed Care Pharmacy. Academy of Managed Care Pharmacy. doi:10.18553/jmcp.2002.8.4.266.
~42 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top